Related Experiment Video
Updated: May 26, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's
M Cuadrado-Tejedor1, A García-Osta, A Ricobaraza
1Cellular and Molecular Neuropharmacology, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Avda Pío XII 55, E-31008 Pamplona, Spain.
Abstract:
4-phenylbutyrate (PBA) is a small molecule that restores cognitive deficits in animal models of Alzheimer's disease (AD). Although the molecular basis of the cognitive benefits of PBA remains unknown, a multi-modal/multi-target mechanism has been proposed. Putative targets of this drug are different from those of drugs that are now used in clinical trials. As PBA is already administered to patients with congenital defects affecting enzymes in the urea cycle, it can be rapidly tested in AD clinical trials. However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day). Thus, deciphering the precise mechanism(s) of action of this drug may enable novel drugs with similar therapeutic effects to PBA to be developed that can be used at more manageable doses.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Alzheimer Disease l: Introduction